AXA Framlington Health Fund Z Acc
Healthcare and BiotechnologyPricing frequency
Daily
Dealing cut off time
11:00
Type
Unit Trust
Yield
0.12%
NAV
508.30p
Income frequency
Semi-annually
Ongoing charge
0.82%
Latest actual NAV date
16-11-2026
ISIN
GB00B6WZJX05
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 31/10/2026 | % of assets |
|---|---|
| Eli Lilly and Co | 9.08 |
| Thermo Fisher Scientific Inc | 5.57 |
| UnitedHealth Group Inc | 4.77 |
| Teva Pharmaceutical Industries Ltd | 4.32 |
| Natera Inc | 4.00 |
| Novartis AG Registered Shares | 3.95 |
| Roche Holding AG Ordinary Shares new | 3.89 |
| AbbVie Inc | 3.89 |
| AstraZeneca PLC | 3.26 |
| Danaher Corp | 3.08 |
Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed healthcare companies including producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers and other healthcare services companies, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world albeit the Fund tends to be biased towards the US, as this is where the majority of healthcare related companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.